|
Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations. |
| |
|
Consulting or Advisory Role - Celgene; Merck Serono; Shire |
Speakers' Bureau - Celgene |
Research Funding - Celgene |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Bayer; Genentech/Roche; Merck Serono; Novartis; Taiho Pharmaceutical |
Research Funding - Array BioPharma; AstraZeneca; Green Cross; Lilly; Novartis |
| |
|
No Relationships to Disclose |
| |
|
Travel, Accommodations, Expenses - Agios; Roche/Genentech; Roche/Genentech |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Employment - Janssen Research & Development |
Travel, Accommodations, Expenses - Janssen Research & Development |
| |
|
|
Stock and Other Ownership Interests - Janssen |
Travel, Accommodations, Expenses - Janssen |
| |
|
Employment - Johnson & Johnson |
| |
|
|
| |
|
|
| |
|
|
| |
|
|
Stock and Other Ownership Interests - Johnson & Johnson |
| |
|
Employment - Johnson & Johnson |
Stock and Other Ownership Interests - Johnson & Johnson |